Pharmaceutical Breakthroughs: Alzheimer's and Cancer Immunotherapy in India

Two days. That’s all it took. India just crossed two massive pharmaceutical lines, one hitting the brain, one hitting the lungs. It feels like a sudden shift, doesn’t it?

Eli Lilly’s Lormalzi , that’s the name for their Donanemab , hit the market on Wednesday. It’s the first drug available here that actually aims at Alzheimer’s disease itself, not just the symptoms you see later. It’s trying to tackle the root cause—those amyloid plaques in the brain.

Then, Thursday, Roche rolled out Tecentriq SC . That’s the subcutaneous version of their lung cancer immunotherapy. It’s the same molecule as the IV version, but the delivery is totally different. Instead of a long, hour-long drip, people get it injected into the thigh or arm. Seven minutes. That’s the headline for that one.

The jobs these two drugs do? They are worlds apart.

Donanemab is about the brain. It’s trying to bend the trajectory of Alzheimer’s by clearing out those plaques. But there’s a huge catch there. It only works for the very early stages. The window for catching it, the time you actually need to intervene, that’s something most Indian families just miss.

Tecentriq SC , though. That’s about cancer immunotherapy. It changes the logistics entirely. It saves hours. It clears out those overloaded oncology day-care units. That’s a huge practical win for patients dealing with cancer.

But let’s talk about the money.

Lilly’s Donanemab ? It’s priced at Rs 91,688 per vial. That’s for a monthly infusion. And the regulators—the CDSCO and the US FDA—they cleared it, sure. But only for mild cognitive impairment or mild dementia related to Alzheimer’s. Not for the hard, advanced stuff. Lilly even flagged some kind of Alternate Access Programme, which means there’s still a real barrier.

Then there’s the cancer side. Tecentriq SC , that subcutaneous shot? That’s priced at a staggering Rs 3.70 lakh per vial. That’s a lot of money just to get the delivery method changed. The actual drug payload hasn't changed, mind you. It’s still atezolizumab paired with that special platform to get it under the skin. The only real shift is how fast it gets delivered.

Lilly’s Donanemab is a humanized antibody. It goes around and tags those amyloid-beta plaques so the brain’s own cleanup crew, the microglia, can finally start clearing them. The clinical trials, TRAILBLAZER-ALZ 2, showed a decent slowdown—about 35% in cognitive decline over eighteen months, especially for those with less tau burden. But you have to look at the risks. There are those scary things, the amyloid-related imaging abnormalities, the swelling, the microhaemorrhages you can see on an MRI. It’s not all smooth sailing.

Dr Manjari Tripathi, who heads neurology at AIIMS Delhi, she hit the nail on the head. She said you need to get patients in much earlier. She stressed that the drug is only for the very early stages. She warned that the side effects—the swelling, the bleeding—they happen. You need proper consent, real counseling. Meta-analyses aren’t screaming dramatic effects, but you still have to be careful.

“Patients need to present very, very early,” she insisted. “But in India, most people arrive in the middle stage of dementia. This demands a total shift. Relatives have to bring the patients in much sooner.”

It’s that kind of caution that hangs over everything.

Dr Sanjay Pandey, from Amrita Hospital, he talked about the whole landscape of Alzheimer’s care. For decades, it was mostly about managing symptoms. Clinicians watched decline happen, and they tried their best to support the patient. Now, donanemab throws a wrench in that old view. It’s pushing the conversation away from just managing symptoms and toward actually modifying the disease itself, but only in these carefully picked patients.

He pointed out the bigger picture for a place like India. With dementia rates creeping up and people living longer, this forces us to look at diagnosis, biomarkers, better imaging, and specialized memory care pathways. But he added the necessary brake: caution. “Patient eligibility, risk stratification, constant monitoring, and having multidisciplinary neurology oversight—that’s the only way to get real results.”

Now, switch gears completely. Let’s look at the cancer side.

Tecentriq , the subcutaneous version, is a PD-L1 inhibitor. Think of it this way: cancer cells are smart. They put out a signal, PD-L1, telling the immune system’s T-cells to just chill out. Atezolizumab blocks that signal. It stops the ‘stand down’ order, letting the immune system fight back properly.

The crucial thing is that the subcutaneous version is pharmacologically identical. It’s the same drug. The only difference is the delivery system. The clinical trials proved this equivalence. The subcutaneous version worked just as well, just differently.

In the Phase 3 trials, there was a real choice for the patients. Seventy-one percent of people preferred the shot after trying both options. Seventy-nine% chose to stick with it. It’s not about achieving better survival rates, not exactly. It’s about the experience. Less time stuck in the hospital chair. Less strain on the healthcare infrastructure. A less invasive experience overall.

Dr Pragya Shukla, head of oncology at Delhi State Cancer Institute, she framed it perfectly. She said this shift in delivery is huge. Immunotherapy used to mean long infusions, repeated hospital visits. Now, a subcutaneous delivery cuts down the time. It makes treatment way more convenient. It saves resources.

She spoke about the atmosphere in oncology settings. “Shorter administration times,” she said, “they help us optimize resources and improve patient flow. It reflects how cancer care is changing—it’s about better outcomes *and* a better experience for the patient.”

But even with that efficiency gain, the elephant in the room remains. Dr Manish Kumar, a medical oncologist in Bengaluru, he brought the reality back into focus. He said the subcutaneous option is definitely a step toward making cancer treatment friendlier. But he immediately hit the snag. Access. Affordability.

He pointed directly at that price tag—Rs 3.70 lakh per vial. That’s where the innovation meets the reality of the Indian healthcare system. “For Indian patients, the real impact isn’t just the clinical benefit,” he insisted. “It depends entirely on insurance coverage, patient assistance programs, and making sure access is truly equitable.”

It’s that friction, isn't it? The incredible science is out there, these new tools, but getting them into the hands of the people who need them, safely and affordably, that’s the real, messy part of the story. It’s a complicated mix of scientific breakthrough and sheer logistical headache.